# Ivabradine to Prevent Anthracycline-induced Cardiotoxicity

> **NCT03650205** · NA · UNKNOWN · sponsor: **University of Sao Paulo** · enrollment: 160 (estimated)

## Conditions studied

- Neoplasms
- Heart Failure
- Cardiotoxicity
- Chemotherapy Effect
- Oncology

## Interventions

- **DRUG:** Ivabradine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03650205
- **Lead sponsor:** University of Sao Paulo
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-01-22
- **Primary completion:** 2021-10-01
- **Final completion:** 2021-12-01
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2019-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03650205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03650205, "Ivabradine to Prevent Anthracycline-induced Cardiotoxicity". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03650205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*